Your browser doesn't support javascript.
loading
Safety of intravitreal metoprolol in eyes with central serous chorioretinopathy.
Gonçalves, Annelise Nicotti; Messias, André; Chaves, Leandro; de Azeredo Bastos, Thaís Marino; Jorge, Rodrigo.
Afiliação
  • Gonçalves AN; Department of Ophthalmology, Ribeirão Preto School of Medicine, University of São Paulo, 3900, Bandeirantes Avenue, Ribeirão Preto, SP,, 14049-900, Brazil.
  • Messias A; Department of Ophthalmology, Ribeirão Preto School of Medicine, University of São Paulo, 3900, Bandeirantes Avenue, Ribeirão Preto, SP,, 14049-900, Brazil. amessias@usp.br.
  • Chaves L; Department of Ophthalmology, Ribeirão Preto School of Medicine, University of São Paulo, 3900, Bandeirantes Avenue, Ribeirão Preto, SP,, 14049-900, Brazil.
  • de Azeredo Bastos TM; Department of Ophthalmology, Ribeirão Preto School of Medicine, University of São Paulo, 3900, Bandeirantes Avenue, Ribeirão Preto, SP,, 14049-900, Brazil.
  • Jorge R; Department of Ophthalmology, Ribeirão Preto School of Medicine, University of São Paulo, 3900, Bandeirantes Avenue, Ribeirão Preto, SP,, 14049-900, Brazil.
Doc Ophthalmol ; 145(3): 211-219, 2022 12.
Article em En | MEDLINE | ID: mdl-36333649
PURPOSE: To investigate ocular safety of intravitreal metoprolol in eyes with central serous chorioretinopathy. METHODS: Five eyes of five patients diagnosed with chronic central serous chorioretinopathy (cCSC) previously treated unsuccessfully with oral spironolactone, micropulse laser and intravitreal anti-vascular endothelial growth factor agents were enrolled and received off-label intravitreal metoprolol (50 µg/0.05 ml). Baseline and follow-up examinations included measurement of best-corrected visual acuity (BCVA), intraocular pressure, anterior chamber cellular/flare scores, vitritis classification, fluorescein and indocyanine green angiography, spectral domain optical coherence tomography and electroretinography (ERG), recorded by means of DTL electrodes and following the standard suggested by the International Society for Clinical Electrophysiology of Vision (ISCEV). The total follow-up period was 4 weeks. RESULTS: There were no significant differences between baseline and follow-up ERG parameters: scotopic or photopic, a- and b-wave amplitude and implicit time, nor oscillatory potentials amplitude, or whatsoever. No intraocular inflammation sign was observed. In addition, BCVA showed small improvement in 4 or kept baseline values in 1 patient. The subretinal and/or intraretinal fluid volume reduced in all patients at 1 month after treatment. CONCLUSION: Patients with refractory cCSC treated with intravitreal 50 µg/0.05 ml metoprolol showed no signs of acute ocular toxicity, along with intraretinal fluid reduction and slight BCVA improvement 1 month after injection. This data suggest that intravitreal metoprolol may be a safe alternative for cCSC.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Coriorretinopatia Serosa Central Tipo de estudo: Diagnostic_studies / Observational_studies Limite: Humans Idioma: En Revista: Doc Ophthalmol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Brasil País de publicação: Holanda
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Coriorretinopatia Serosa Central Tipo de estudo: Diagnostic_studies / Observational_studies Limite: Humans Idioma: En Revista: Doc Ophthalmol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Brasil País de publicação: Holanda